China NMPA Drug Inspection - The other 10 companies (see attached list for details) - 11 batches of medicines

On September 11, 2020, the Gansu Provincial Drug Administration, operating under the framework of the National Medical Products Administration (NMPA), issued a formal quality announcement regarding pharmaceutical non-compliance. Following sampling inspections conducted by the Jiayuguan Municipal Food, Drug and Medical Device Testing Center and other institutions, 12 batches of drugs from 11 different companies were found to have failed mandatory quality standards. One of the primary entities identified in the report is Bozhou Huayun Traditional Chinese Medicine Pieces Co., Ltd. The violations cited involve failures in physical properties—such as appearance, texture, and odor—as well as issues with identification testing and the accurate determination of active ingredient content. These failures indicate that the drugs did not meet the necessary benchmarks for safety, authenticity, and therapeutic efficacy. In response, regulatory authorities have seized and sealed the substandard products and initiated formal investigations, with results to be made public within three months. Furthermore, local market supervision bureaus have been ordered to increase oversight, requiring the involved companies to investigate the root causes of these failures and implement comprehensive rectification measures to eliminate potential public health risks.